Last reviewed · How we verify

ChAdOx1 nCoV-19 single dose + paracetamol

University of Oxford · Phase 3 active Biologic

ChAdOx1 nCoV-19 single dose + paracetamol is a Viral vector vaccine Biologic drug developed by University of Oxford. It is currently in Phase 3 development for COVID-19 prevention in adults.

ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19, combined with paracetamol for symptomatic relief.

ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19, combined with paracetamol for symptomatic relief. Used for COVID-19 prevention in adults.

At a glance

Generic nameChAdOx1 nCoV-19 single dose + paracetamol
SponsorUniversity of Oxford
Drug classViral vector vaccine
TargetSARS-CoV-2 spike protein
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to introduce genetic instructions for producing the SARS-CoV-2 spike protein, triggering both cellular and humoral immune responses. Paracetamol is co-administered to manage vaccine-related fever and pain. This combination approach aims to provide protective immunity against SARS-CoV-2 infection while mitigating common post-vaccination symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ChAdOx1 nCoV-19 single dose + paracetamol

What is ChAdOx1 nCoV-19 single dose + paracetamol?

ChAdOx1 nCoV-19 single dose + paracetamol is a Viral vector vaccine drug developed by University of Oxford, indicated for COVID-19 prevention in adults.

How does ChAdOx1 nCoV-19 single dose + paracetamol work?

ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19, combined with paracetamol for symptomatic relief.

What is ChAdOx1 nCoV-19 single dose + paracetamol used for?

ChAdOx1 nCoV-19 single dose + paracetamol is indicated for COVID-19 prevention in adults.

Who makes ChAdOx1 nCoV-19 single dose + paracetamol?

ChAdOx1 nCoV-19 single dose + paracetamol is developed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).

What drug class is ChAdOx1 nCoV-19 single dose + paracetamol in?

ChAdOx1 nCoV-19 single dose + paracetamol belongs to the Viral vector vaccine class. See all Viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is ChAdOx1 nCoV-19 single dose + paracetamol in?

ChAdOx1 nCoV-19 single dose + paracetamol is in Phase 3.

What are the side effects of ChAdOx1 nCoV-19 single dose + paracetamol?

Common side effects of ChAdOx1 nCoV-19 single dose + paracetamol include Injection site pain, Fatigue, Headache, Myalgia, Fever, Chills.

What does ChAdOx1 nCoV-19 single dose + paracetamol target?

ChAdOx1 nCoV-19 single dose + paracetamol targets SARS-CoV-2 spike protein and is a Viral vector vaccine.

Related